Age Limit for Clinical Trial for Pre-implantation Genetic Screening
Ministry of HealthSpeakers
Summary
This question concerns the eligibility criteria for the three-year Pre-Implantation Genetic Screening (PGS) clinical trial at the National University Hospital. MP Louis Ng Kok Kwang asked about the rationale for the age 35 limit and if exceptions could be made for younger women. Minister for Health Gan Kim Yong explained that women under 35 qualify if they have had two or more recurrent implantation failures or pregnancy losses. The 35-year age threshold for other participants is based on medical evidence showing a significantly higher risk of chromosomal abnormalities in babies born to older mothers. Minister for Health Gan Kim Yong noted that this policy aligns with international recommendations from countries like the United Kingdom and Canada.
Transcript
25 Mr Louis Ng Kok Kwang asked the Minister for Health (a) what are the reasons for setting the criteria disallowing women below the age of 35 to take part in the three-year clinical trial for Pre-Implantation Genetic Screening (PGS); (b) whether the Ministry will consider lowering this age limit for women; and (c) whether the Ministry will consider allowing women below the age of 35 to take part on a case-by-case basis.
Mr Gan Kim Yong: Pre-Implantation Genetic Screening (PGS) is a test for chromosomal abnormalities in embryos created through in vitro fertilisation (IVF), before the embryos are implanted into the uterus. MOH recently approved a three-year pilot for PGS. This will commence at the National University Hospital (NUH) in 2017.
Under the pilot programme, patients who fulfil at least one of the following clinical criteria will be eligible
a. Age 35 years old and above, regardless of prognosis
b. Two or more recurrent implantation failures, regardless of age
c. Two or more recurrent pregnancy losses, regardless of age
In other words, women of any age can participate in the pilot if they have had two or more recurrent implantation failures or pregnancy losses. For those without recurrent implantation failures or pregnancy losses, the minimum age is set at 35 years. This is because literature evidence and overseas experience have shown that the chance of a baby born with chromosomal abnormalities for mothers aged 35 and above is significantly higher. Countries such as the UK and Canada have similarly recommended that PGS be made available to women aged 35 years and above, regardless of prognosis.